| 产品描述： | Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer |
| 靶点： |
TGF-beta/Smad;PI3K;Apoptosis;TGF-beta/Smad |
| 体内研究： |
Disitertide (Topical application, 300 μg/mL) may promote scar maturation and improvement of hypertrophic scar morphology features in an “in vivo” model in nude mice after two weeks of treatment Animal Model: Human hypertrophic scars were implanted in 60 nude mice. Dosage: 300 μg/mL was added the Lipogel. Administration: Topical application daily administered. Result: Successful shedding was achieved in 83,3% of the xenografts. |
| 参考文献： |
1. Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31. 2. Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43(5):2212-2220. 3. Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654. 4. Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an In Vivo Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10(12):e0144489. 5. Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381(1):67-75. |
| 溶解性： |
Soluble in H2O |
| 保存条件： |
-20°C |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
0.633 ml |
3.163 ml |
6.326 ml |
| 5 mM |
0.127 ml |
0.633 ml |
1.265 ml |
| 10 mM |
0.063 ml |
0.316 ml |
0.633 ml |
| 50 mM |
0.013 ml |
0.063 ml |
0.127 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京